Clinical Trial: A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07310420) titled 'A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer' on Dec. 16.

Brief Summary: The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH).

Study Start Date: Dec. 29

Study Type: INTERVENTIONAL

Condition: Advanced Breast Cancer

Intervention: DRUG: ZOLADEX

Participants will receive ZOLADEX as a subcutaneous (SC) injection on Day 1 (Week 1), and Day 85 (Week 12) for a total of 2 treatments.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: TerSera Therapeutics L...